We discovered B-lymphocyte-deficient mice within a group of B10.A-CD45.1 mice, and established that this deficiency was a recessively inherited trait. Gene mapping and sequence analysis showed a mutation in the third exon of the Cd79b gene (c.224G4A) that leads to the generation of a stop codon (W75X) in the mutant mouse. Fluorescent-activated cell sorting analysis of bone marrow cells showed that the mutant mice did not express the CD79B antigen. To establish where the block in development happens, we analyzed CD43 pos B220
Introduction
Primary immunodeficiency manifested by agammaglobulinemia and absence of circulating B lymphocytes is the most common congenital immune deficiency. 1 Since 1993, when the first gene responsible for agammaglobulinemia was identified, 2, 3 knowledge of the genome and progress in DNA sequencing have facilitated the discovery of mutations in several other genes in patients with agammaglobulinemias. 1 The most recently reported gene was, CD79B, coding for CD79B antigen (also known as Igb) with mutations found in two patients. 4, 5 Genetically manipulated mice are useful tools for elucidating mechanisms and testing treatment approaches for human diseases. One disadvantage, however, is the need to backcross for many generations to isolate the manipulated gene from other potential operators. Even after many generations, it is difficult to ensure that the observed phenotype is not the result of a linked locus. In the case of agammaglobulinemia, in which patients mostly have hypomorphic point mutations, mouse models with similarly restricted defects would be the most ideal for the research.
In this report, we describe a novel mouse with a spontaneous mutation in the Cd79b gene leading to a block in B-cell development and agammaglobulinemia.
Results and discussion
While isolating organs from a group of B10.A-CD45.1 mice, we noticed that 2 mice out of 16 did not have Peyer's patches, and suspected that the absence of B lymphocytes might be the possible cause 6, 7 and analyzed spleens of these mice for B220-positive cells. We found o0.5% B220 pos cells, confirming that these two mice did not have peripheral B cells. Investigating further, we analyzed blood from other mice of the same line from the same vendor and found that 7 out of 30 of those mice did not have blood-borne B cells.
To determine whether this observation was the result of an inheritable mutation (as opposed to, for example, a B-cell-depleting virus), we crossed B-cell-negative mice to B-cell-positive mice of the same strain. 100% of the F1 pups had blood-borne B cells, whereas B20% (10/51) of the F2 generation were negative, showing a clear recessive inheritance of the trait ( Figure 1a) . As a complementation test, we also crossed the B-cell-negative mice to a strain of B-cell-negative mice that contained mutation in the immunoglobulin locus (mMT mutated in the 3 0 end of the m-heavy chain), and found that 100% of the F1 progeny contained B cells (not shown). Thus, the new mutant was unlikely to be located within the immunoglobulin locus.
To identify the mutation responsible for the absence of B cells in the mutant mice, we crossed the B-cell-negative mice with normal mice of strain 129SVE and screened the F2 progeny for the presence of circulating B cells. As expected for a recessively inherited trait, B25% (94/389) of the F2 mice were affected. Using strainspecific genetic markers, we found that the affected locus mapped to a 10 Mb region between rs3723163 and rs13481240 on chromosome 11 (Figure 1b W75X mutation were bred in the Taconic Farms NIAID contract facility. For gene mapping studies, (mutant Â 129/SvEv) F 1 mice were intercrossed to generate F 2 progeny, which were screened for presence of B cells in peripheral blood. DNA samples from 10 affected F 2 mice, two F 1 mice, one 129SVE and one B10.A (the background strain in which the mutant mice were found) mouse were genotyped for strain-specific SNPs using the SNP array from Illumina (mouse low density linkage panel; San Diego, CA, USA) by the Partners HealthCare Center for Personalized Genetic Medicine (PCPGM), Harvard Medical School, Boston, USA. Cd79b gene and the promoter region were sequenced in the mutant (two pool samples, each pool containing DNA samples from two individual mice) and B10.A-CD45.1 mice (one DNA pool sample containing samples from five individual mice). Experiments were approved by the NIAID Animal Care and Use Committee at NIH, which is accredited by the AALAC. The mutant mouse B10.CgPtprc a Cd79b m1Ghost H2 a is registered in the MGI database under accession number 3829352. FACS (fluorescent-activated cell sorting) staining: proteins expressed on the surface of blood and bone marrow cells were stained following standard protocols. The fluorochrome-conjugated antibodies were B220-PE (clone RA3-6B2; BD Pharmigen, San Jose, CA, USA) and anti-CD79B-FITC (clone HM79b; BD Pharmigen); 7-aminoactinomycin D (7AAD; BD) was used to identify living cells. Data were acquired on a BD FACSCant FACSCanto II flow cytometer and analyzed using FlowJo software. 8 in the mutant and wild-type mice, we identified a mutation in exon 3 c.224G4A that leads to generation of a stop codon (TGG4TAG; W75X) in the mutant mouse (Figure 1c ).
Spontaneous mutation in
The mutation was in the Ig-like domain of CD79b, which is responsible for binding of Igb to Iga. The two molecules together constitute the signaling part of the B-cell antigen-receptor complex, which is expressed throughout B-cell development, from early B-cell precursors to plasma cells. As expected, FACS (fluorescent-activated cell sorting) analysis of bone marrow cells showed that the mutant mice did not express the CD79B antigen, whereas it was strongly expressed on B220 pos cells in wild-type mice (Figure 1d) 12 The authors did not find clear differences in the distributions of these fractions between Cd79b KO and wild-type mice. However, because the early pre-B cells (fraction C 0 ) are the first cells to appear after receiving a signal through IgMIgb-Iga complex that stimulates them to enter the cell cycle, 12 we surmised that these cells should be missing in the KO mouse (because the pre-BCR complex is not formed). Therefore, we analyzed the proportions of cells undergoing B-cell development in the bone marrow of the new mutant, which in principle should resemble the Cd79b KO mouse. Indeed there were several features in common between the new mutant and the Cd79b KO, but also some striking differences. As in the original report on the KO mouse, we found that the B-cell development seemed to stop at the CD43 pos B220 pos stage (Figure 2a ). However, in contrast to the previous work, we found dramatic changes in the distribution of the cells in fractions A-C. Using CD24 and BP-1 surface staining, 13 we found that fraction C 0 was virtually absent in the CD79b-mutant mouse, whereas fractions B and C showed a relative accumulation (Figure 2b ). Such accumulation would be expected if the mutant B cells were unable to receive a signal through the B-cell receptor (BCR), as both fractions are immediate precursors of the C 0 cells. 14 This result suggests that the Cd79b gene product is necessary for progression into the C 0 stage, and fits well with current knowledge of the Bcell development process, which holds that cells in fraction C 0 are large, proliferating pre-B cells that have recently received a functional signal through the pre-BCR complex. 15 There are two potential reasons why we obtained different results from those previously published on the Cd79b KO mouse. The first is that C and C 0 populations in B6 mice have been difficult to discriminate by FACS (personal communication from R Hardy). The last decade has seen a great deal of technological improvement in flow-cytometry that allowed us to overcome this problem. The second reason is related to the methods by which the mutations were generated. Our mutant mouse is a spontaneous mutant that has only a single point mutation, the remainder of its genome coming from the inbred line. This provides a unique opportunity to estimate precisely where the block in development occurs, without the effect of any other potential confounding factors that may exist in a KO mouse, in which it is difficult to rule out the effect of other genes that may not have been removed during the backcrossing process.
Some investigators have found low levels of IgA in mMT B-cell KO mice, 16 which have a block in the development of B cells at a stage similar to our mutant. Others, however, have not, 17 and human patients with similar mutations lack IgA. 18 We therefore measured levels of total IgA and IgG in the blood of Cd79b mutant, in control heterozygous mice, and in mMT B-cell KO mice and their corresponding controls. We found neither IgA nor IgG in the Cd79b mutant or the mMT B-cell KO mice (Figure 3 ). Although it is still not clear why our results in the mMT mice differ from those of Macpherson et al., one hypothesis is that it relates to differences in the flora of the different mouse colonies. In addition, Hasan et al. have shown that there is an additional locus that is not linked to immunoglobulin locus, which is critical for differences in immunoglobulin production between mMT B-cell KO mice on BALB/c and B6 backgrounds. The result regarding the absence of immunoglobulins in Cd79b mutant is quite straightforward and is in agreement with aglobulinemias in CD79B-mutant patients. 4, 5 Different mutations in the Cd79b gene can lead to different outcomes. For example, leukemia has been reported in human patients with mutations in CD79B gene that lead to changes in the protein, but not to its complete or significant ablation. 19 Notably, the mutation Immunoglobulin levels were measured in serum samples using ELISA kits from Immunology Consultants Lab Inc (Newberg, OR, USA). Mice were females, 3-6 months of age; the background strain for all mice was B10.A. The original mutant and wild-type mice were obtained from the NIAID contract facility at Taconic Farms, and bred to N2 generation to obtain mutant and heterozygous littermates.
Spontaneous mutation in Cd79b gene in mice N Shulzhenko et al found in the new mouse reported here is remarkably similar to the mutations found in two immunodeficient patients who had mutations in the CD79B gene. Indeed, both patients had mutations leading to a stop codon in the third exon of the CD79B gene, and had no or extremely low numbers of B cells and antibodies. 4, 5 These results suggest that this new mutant strain could be a useful tool for immunological research into the human immunodeficiencies, as it closely resembles the phenotype of the immunodeficient human patients; it has a homogeneous inbred genome, a congenic marker and a wild-type strain that differs only by this single mutation.
